Yazar "Kaya, Hakki" seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Arginine vasopressin and difficult triangle of heart failure, atrial fibrillation, and hyponatremia(Hellenic Cardiological Soc, 2020) Kaya, Hakki; Cavusoglu, Yuksel[Anstract Not Available]Öğe Association between stasis dermatitis and length of stay in heart failure hospitalizations(Wolters Kluwer Medknow Publications, 2020) Kaya, Ozge; Sahin, Anil; Kaya, HakkiBackground: Stasis dermatitis (SD) is caused by venous hypertension that can be associated with peripheral congestion due to heart failure (HF). Length of stay (LOS) is the primary driver of HF hospitalization costs. Therefore, it is important to determine those patients who will have longer LOS. We aimed to investigate the relationship between the SD and LOS in HF patients. Methods: A total of 308 patients, who were hospitalized between January 2012 and January 2014 due to acute decompensated HF (ADHF) in our center, were evaluated in this retrospective observational cohort study. Patients' baseline clinical characteristics and presence of SD diagnosis within the past 3 months prior the HF hospitalization were assessed by a review of cardiology and dermatology clinics medical records. Results: A total of 237, acutely decompensated, HF patients were enrolled in the study. The median LOS was 5 days, and the mean LOS was 5.4 ± 2 days. Prolonged LOS was defined as LOS >5 days, and the patients were classified into two groups: Those with LOS ?5 days (Group I) and those with LOS >5 days (Group II, longer LOS). The presence of SD diagnosis was higher in Group II compared to patients in Group I (22% vs. 46%, P < 0.001). In the multivariate logistic regression model, presence of SD diagnosis, presence of moderate-to-severe tricuspid regurgitation, presence of atrial fibrillation, left atrial diameter, creatinine level, sodium level remained associated with longer LOS after adjustment for age, gender and for the variables found to be statistically significant in univariate analysis and correlated with LOS. Conclusions: This was the first time in the literature that a study demonstrated that the presence of SD was associated with an increased the risk of prolonged hospitalization independent of other factors in patients with reduced ejection fraction heart failure admitted for ADHF. © 2020 Society of Cardiovascular Academy. All rights reserved.Öğe Olfactory dysfunction may predict myocardial injury in COVID-19 patients(Churchill Livingstone, 2020) Aksit, Ercan; Cil, Ozge Caglar; Kaya, Hakki[Anstract Not Available]Öğe Relationship between sST2 levels and prognosis in patients with pulmonary arterial hypertension(Bayrakol Medical Publisher, 2020) Sahin, Anil; Kaya, Hakki; Gul, IbrahimAim: Soluble Suppression of Tumorigenicity-2 (sST2) was approved for non-invasive risk assessment and its prognostic benefits were monitored in some heterogeneous pulmonary hypertension cohorts. In this study, we aimed to evaluate the relationship of sST2 use with clinical deterioration and survival in pulmonary arterial hypertension (PAH) patients. Material and Method: Forty-one patients (36 women, 5 men) who were followed due to known PAH were included in the study. The primary endpoint was determined as clinical deterioration. Results: At the end of the mean 6 +/- 2 months follow-up period, in total, 14 patients (34%) exhibited clinical deterioration and 7 patients (17%) died. Patients having WHO-FC III-IV, high sST2, and NT-proBNP levels and low 6-MWT presence were associated with clinical deterioration (p<0.001). Also, sST2 and NT-proBNP levels were significantly higher in patients who died during follow-up (p=0.004 and p=0.003, respectively). In the multivariate Cox proportional hazards model with the forward stepwise method, TAPSE (HR=0.587, 95% CI: 0.419-0.823, p=0.002) and sST2>51 ng/ml on admission (HR=9.653, 95% CI: 4.074-82.249, p=0.004) remained associated with an increased risk of clinical deterioration. Discussion: This study shows that sST2 levels can provide some information in determining clinical impairment in PAH patients. This is compatible with previous studies showing high levels of sST2 in PAH patients. sST2 levels were shown to be an independent predictor of clinical deterioration on PAH.Öğe Serum glycoprotein 96, a heat shock protein 90 paralog, as a potential biomarker in psoriasis: a prospective case-control study(Springer, 2026) Kaya, Ozge; Sehitoglu, Muserref Hilal; Mermutlu, Selda Isik; Kilic, Sevilay Oguz; Kaya, HakkiPsoriasis is a chronic, immune-mediated skin disease characterized by keratinocyte stress and cytokine-driven inflammation. Glycoprotein 96 (gp-96), a heat shock protein 90 paralog located in the endoplasmic reticulum, plays a critical role in the folding of Toll-like receptors and may contribute to the amplification of inflammatory responses. This study investigated serum gp-96 levels in patients with psoriasis compared to healthy controls and explored potential associations with clinical features. A total of 44 psoriasis patients and 44 healthy individuals were enrolled in a prospective case-control study. Serum gp-96 concentrations were quantified using ELISA. Patients' demographic and clinical data, including PASI scores, nail and joint involvement, and treatment modalities, were collected. Serum gp-96 levels were significantly higher in psoriasis patients than in healthy controls (median 15.92 vs. 9.33 ng/mL, p < 0.001). However, gp-96 levels did not correlate significantly with PASI score, age, disease duration, or other clinical variables. ROC analysis revealed that serum gp-96 has good diagnostic performance in distinguishing psoriasis patients from controls, with an AUC of 0.83 and an optimal cut-off value of 11.57 ng/mL (sensitivity and specificity: 77.3%). A borderline association with nail involvement was observed, suggesting a potential link between gp-96 levels and localized keratinocyte stress. These findings suggest that gp-96 may be a promising diagnostic biomarker in psoriasis, independent of disease severity, and could play a role in the pathogenesis of the disease through its involvement in ER stress and innate immune activation. Further studies with larger cohorts and tissue-level investigations are warranted to validate these results and explore the therapeutic potential of targeting gp-96 in psoriatic disease.
